Pharmaceutical Sector

More than half of women suffer from premenstrual symptoms, which causes both physical and emotional trauma. But shortly with the help of a low-dose medicine, it might be easier to deal with premenstrual problems.

Researchers at the Birmingham University say that low doses of the anti-depression drug Prozac can be beneficial in the reduction of the premenstrual symptoms like mood swings, fatigue, irritability, headaches, and joint pains.

Due to FDA’s decision to further delay the review of AstraZeneca’s heart drug Brilinta, the Company witnessed a slide in its share prices making European shares declined by midday on Wednesday. But, the loss was compensated by the advancement in the stock prices of car makers.

The pan-European FTSEurofirst 300 index of chief shares at 1046 GMT dropped 0.3% to 1,084.14 points. In September, it increased 5.6% and the analysts showed positivity by saying that the index is still giving some of the profits.

Spanish Medicines and Health Products Agency is reported to have granted its nod to Sylentis, powering it to start with a second Phase I/II clinical trial on its new drug being designed to serve as a part in the treating ocular hypertension.

Sylentis is a subsidiary of Grupo Zeltia and hails to be a leader in the field of developing new gene silencing treatments and therapies, also known as interference RNA (RNAi).

The approval has been granted after the Phase I trial of the drug fetched success.

The US Food and Drug Administration has granted approval to the Indian generic-drug maker Lupin Ltd. for a generic version of Pfizer Inc.'s cholesterol drug Lipitor. Also, reports have said that Lupin has gained 1.83% to Rs.367.15 at 14:26 IST on BSE. At 09:28 hours, the shares were at Rs. 364.80, up Rs. 4.25, or 1.18%.

In addition to this, the BSE Sensex had also fallen 2.70 points, or 0.01% to 18,235.61. In the past one quarter on BSE, an average daily volume of 28,722 shares were traded; whereas, this time, 73,365 shares were traded in the counter.

On August 30, Genzyme Corp. declined to go ahead with the Sanofi-Aventis AG’s acquisition bid of $18.5 billion or $69-a-share, as the Company undervalued the worth of the former.

In a letter to Sanofi, Henri A. Termeer, Genzyme’s Chief Executive said, “The Genzyme board is not prepared to engage in merger negotiations with Sanofi based upon an opportunistic proposal with an unrealistic starting price that dramatically undervalues our company’’.